Atrogi宣布发表关于对抗肥胖和代谢并发症的进展-动脉网 (2024)

Preclinical data shows precision modulation of beta-2 and beta-3 signaling boosts metabolism and enhances body recomposition

临床前数据显示，β-2和β-3信号的精确调节可促进新陈代谢并增强身体重组

STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of Molecular Metabolism (1). The research paper validates the mechanism of action of the company’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications..

瑞典斯德哥尔摩，2024年5月24日（环球通讯社）--Atrogi是一家领先的临床阶段生物技术公司，致力于推进代谢紊乱的治疗，在《分子代谢杂志》上发表了一篇文章（1）。该研究论文验证了该公司一流的小分子ATR-127在对抗肥胖和代谢并发症方面的作用机制。。

Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass. ATR-127 binds to both the beta-2 and beta-3 adrenergic receptors in a unique manner, allowing for precise modulation of downstream signaling cascades.

与现有的影响瘦肌肉质量的抗肥胖疗法不同，ATR-127在保持关键瘦体重的同时诱导显着的体重减轻。ATR-127以独特的方式与β-2和β-3肾上腺素能受体结合，从而可以精确调节下游信号级联。

Unlike conventional approaches, ATR-127's innovative binding mechanism enables selective activation of specific signaling pathways. This unlocks the full therapeutic potential of beta-2 and beta-3 receptor agonism, maximizing beneficial effects on metabolism and body composition while mitigating the cardiovascular side effects commonly associated with indiscriminate receptor activation..

与传统方法不同，ATR-127的创新结合机制能够选择性激活特定的信号通路。这释放了β-2和β-3受体激动剂的全部治疗潜力，最大程度地提高了对代谢和身体成分的有益作用，同时减轻了通常与不加选择的受体激活相关的心血管副作用。。

Atrogi’s CEO, Alexandra Ekman Ryding, said, “This publication highlights strong pre-clinical data relating to ATR-127 and validates our approach for the development of a novel modality for the treatment of obesity. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”.

Atrogi的首席执行官Alexandra Ekman Ryding说：“本出版物重点介绍了与ATR-127相关的强大临床前数据，并验证了我们开发治疗肥胖症新模式的方法。我们现在正在推进下一代小分子治疗肥胖症，以在明年上半年进行IND准备研究，并有望在2026年进入诊所。”。

Atrogi´s founder and CSO, Tore Bengtsson, a Professor of Physiology at Stockholm University, said, “There is a high demand for novel treatments of obesity without the current debilitating side effects and muscle loss. We believe our pioneering dual receptor beta-agonist approach has the potential to transform the obesity treatment landscape.

Atrogi的创始人兼CSO，斯德哥尔摩大学生理学教授Tore Bengtsson说：“对新型肥胖治疗方法的需求很高，目前没有令人衰弱的副作用和肌肉损失。我们相信我们开创性的双受体β激动剂方法有可能改变肥胖治疗的格局。

Our vision is for a more holistic treatment for diabesity and steatohepatitis that not only treats the underlying cause of disease but also supports overall health and quality of life.”.

我们的愿景是对糖尿病和脂肪性肝炎进行更全面的治疗，不仅可以治疗疾病的根本原因，还可以支持整体健康和生活质量。”。

The study found that ATR-127 enhances energy expenditure and promotes beneficial metabolic changes by inducing skeletal muscle glucose uptake and the concomitant activation of brown and beige adipose tissue. This results in healthy weight loss - decreasing fat mass but preserving muscle, whilst reducing hepatic inflammation and lipid content.

该研究发现，ATR-127通过诱导骨骼肌葡萄糖摄取以及伴随的棕色和米色脂肪组织的激活来增强能量消耗并促进有益的代谢变化。这会导致健康的体重减轻-减少脂肪量，但保留肌肉，同时减少肝脏炎症和脂质含量。

ATR-127’s ability to deliver precise signaling modulation prevents excessive cAMP production thereby lowering cardiac force production and mitigating risks of cardiovascular side effects..

ATR-127提供精确信号调节的能力可防止cAMP产生过多，从而降低心脏力产生并减轻心血管副作用的风险。。

Atrogi宣布发表关于对抗肥胖和代谢并发症的进展-动脉网 (2024)

References